Neal James R 4

What Happened
Neal James R, a director of Processa Pharmaceuticals, acquired 789 shares in an open-market purchase on 2026-03-31 at $2.54 per share. The transaction is reported with a total reported value of $2,000. This was a straightforward purchase (transaction code P), which investors often regard as a more informative signal than routine sales.

Key Details

• Transaction date: 2026-03-31
• Price per share: $2.54
• Shares acquired: 789
• Total reported value: $2,000 (as listed in the filing)
• Transaction type/code: Open-market purchase (P)
• Filing date: 2026-04-02 (filed on Form 4); appears to be timely (Form 4 is typically due within two business days)
• Shares owned after transaction: Not specified in the provided report
• Notable footnotes: None noted in the provided transaction detail

Context
The purchase amount is relatively small (~$2k), so while it indicates the director bought stock, the dollar size limits its weight as a signal about company prospects. This was a direct open-market buy — not an option exercise, gift, or derivative transaction.